Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel specific signature of pediatric MOZ-CBP acute myeloid leukemia.
Serravalle S, Melchionda F, Astolfi A, Libri V, Masetti R, Pession A. Serravalle S, et al. Among authors: libri v. Leuk Res. 2010 Nov;34(11):e292-3. doi: 10.1016/j.leukres.2010.05.026. Epub 2010 Jul 13. Leuk Res. 2010. PMID: 20630590 No abstract available.
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
Astolfi A, Vendemini F, Urbini M, Melchionda F, Masetti R, Franzoni M, Libri V, Serravalle S, Togni M, Paone G, Montemurro L, Bressanin D, Chiarini F, Martelli AM, Tonelli R, Pession A. Astolfi A, et al. Among authors: libri v. Oncotarget. 2014 Jan 15;5(1):120-30. doi: 10.18632/oncotarget.1337. Oncotarget. 2014. PMID: 24334727 Free PMC article.
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R, Secondino S, Schiavetto I, Caliogna L, Locatelli F, Libri V, Pession A, Tonelli R, Maccario R, Siena S, Pedrazzoli P. Montagna D, et al. Among authors: libri v. Cytotherapy. 2012 Jan;14(1):80-90. doi: 10.3109/14653249.2011.610303. Epub 2011 Sep 23. Cytotherapy. 2012. PMID: 21942841 Clinical Trial.
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
Townsley H, Gahir J, Russell TW, Greenwood D, Carr EJ, Dyke M, Adams L, Miah M, Clayton B, Smith C, Miranda M, Mears HV, Bailey C, Black JRM, Fowler AS, Crawford M, Wilkinson K, Hutchinson M, Harvey R, O'Reilly N, Kelly G, Goldstone R, Beale R, Papineni P, Corrah T, Gilson R, Caidan S, Nicod J, Gamblin S, Kassiotis G, Libri V, Williams B, Gandhi S, Kucharski AJ, Swanton C, Bauer DLV, Wall EC. Townsley H, et al. Among authors: libri v. PLoS One. 2024 Mar 21;19(3):e0294897. doi: 10.1371/journal.pone.0294897. eCollection 2024. PLoS One. 2024. PMID: 38512960 Free PMC article.
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
Shawe-Taylor M, Greenwood D, Hobbs A, Dowgier G, Penn R, Sanderson T, Stevenson-Leggett P, Bazire J, Harvey R; Crick COVID Serology Pipeline Investigators, Legacy Investigators; Libri V, Kassiotis G, Gamblin S, Lewis NS, Williams B, Swanton C, Gandhi S, Carr EJ, Wu MY, Bauer DLV, Wall EC. Shawe-Taylor M, et al. Among authors: libri v. Lancet. 2024 Mar 23;403(10432):1133-1136. doi: 10.1016/S0140-6736(24)00316-7. Epub 2024 Mar 11. Lancet. 2024. PMID: 38484752 No abstract available.
126 results